Efficacy of a Novel Pleiotropic MMP-Inhibitor, CMC2.24, in a Long-Term Diabetes Rat Model with Severe Hyperglycemia-Induced Oral Bone Loss

References

• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Supplement1):S81–S90. doi:10.2337/dc14-S081
   Google Scholar
• International Diabetes Federation. IDF Diabetes Atlas. 9th ed. International Diabetes Federation; 2019.
   Google Scholar
• Lalla E, Papapanou PN. Diabetes mellitus and periodontitis: a tale of two common interrelated diseases. Nat Rev Endocrinol. 2011;7(12):738–748. doi:10.1038/nrendo.2011.106
   PubMed Web of Science ®Google Scholar
• Grossi SG, Skrepcinski FB, DeCaro T, et al. Response to periodontal therapy in diabetics and smokers. J Periodontol. 1996;67(10S):1094–1102. doi:10.1902/jop.1996.67.10s.1094
   Google Scholar
• Lalla E, Lamster IB, Feit M, et al. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest. 2000;105(8):1117–1124. doi:10.1172/JCI8942
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Hori O, Chen JX, et al. Advanced glycation end products interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest. 1995;96(3):1395–1403.
   PubMed Web of Science ®Google Scholar
• Stern DM, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation end products (RAGE) and the complications of diabetes. Ageing Res Rev. 2002;1(1):1–15. doi:10.1016/S0047-6374(01)00366-9
   PubMed Web of Science ®Google Scholar
• Mealey BL, Rose LF. Diabetes mellitus and inflammatory periodontal diseases. Curr Opin Endocrinol Diabetes Obes. 2008;15(2):135–141. doi:10.1097/MED.0b013e3282f824b7
   PubMedGoogle Scholar
• Grossi SG, Zambon JJ, Ho AW, et al. Assessment of risk for periodontal disease. I. Risk indicators for attachment loss. J Periodontol. 1994;65(3):260–267.
   PubMed Web of Science ®Google Scholar
• Shiau M-Y, Tsai S-T, Tsai K-J, et al. Increased circulatory MMP-2 and MMP-9 levels and activities in patients with type 1 diabetes mellitus. Mt Sinai J Med. 2006;73(7):1024–1028.
   Google Scholar
• Smith PC, Muñoz VC, Collados L, Oyarzún AD. In situ detection of matrix metalloproteinase-9 (MMP-9) in gingival epithelium in human periodontal disease. J Periodontal Res. 2004;39(2):87–92. doi:10.1111/j.1600-0765.2004.00705.x
   Web of Science ®Google Scholar
• Lazăr L, Loghin A, Bud E-S, et al. Cyclooxygenase-2 and matrix metalloproteinase-9 expressions correlate with tissue inflammation degree in periodontal disease. Rom J Morphol Embryol. 2015;56(4):1441–1446.
   Web of Science ®Google Scholar
• Bastos MF, Tucci MA, de Siqueira A, et al. Diabetes may affect the expression of matrix metalloproteinases and their inhibitors more than smoking in chronic periodontitis. J Periodontal Res. 2017;52(2):292–299. doi:10.1111/jre.12394
   Web of Science ®Google Scholar
• Şurlin P, Oprea B, Solomon SM, et al. Matrix metalloproteinase-7,-8,-9 and-13 in gingival tissue of patients with type 1 diabetes and periodontitis. Rom J Morphol Embryol. 2014;55(3 Suppl):1137–1141.
   Web of Science ®Google Scholar
• Ueland T, Holter J, Holten A, et al. Distinct and early increase in circulating MMP-9 in COVID-19 patients with respiratory failure. J Infect. 2020;81(3):e41–e43. doi:10.1016/j.jinf.2020.06.061
   PubMed Web of Science ®Google Scholar
• Sorsa T, Tjaderhane L, Konttinen YT, et al. Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann Med. 2006;38(5):306–321. doi:10.1080/07853890600800103
   PubMed Web of Science ®Google Scholar
• Björklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta. 2005;1755(1):37–69.
   PubMed Web of Science ®Google Scholar
• Sang Q-X, Birkedal-Hansen H, Van Wart HE. Proteolytic and non-proteolytic activation of human neutrophil progelatinase B. Biochim Biophys Acta. 1995;1251(2):99–108. doi:10.1016/0167-4838(95)00086-A
   PubMedGoogle Scholar
• Fridman R, Toth M, Peña D, Mobashery S. Activation of Progelatinase B (MMP-9) by Gelatinase A (MMP-2). Cancer Res. 1995;55(12):2548–2555.
   PubMed Web of Science ®Google Scholar
• Sorsa T, Tjäderhane L, Salo T. Matrix metalloproteinases (MMPs) in oral diseases. Oral Dis. 2004;10(6):311–318. doi:10.1111/j.1601-0825.2004.01038.x
   PubMed Web of Science ®Google Scholar
• Escalona LA, Mastromatteo-Alberga P, Correnti M. Cytokine and metalloproteinases in gingival fluid from patients with chronic periodontitis. Investigación clínica. 2016;57(2):131–142.
   Web of Science ®Google Scholar
• Vandooren J, Van den Steen PE, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol. 2013;48(3):222–272. doi:10.3109/10409238.2013.770819
   PubMed Web of Science ®Google Scholar
• O’Sullivan S, Medina C, Ledwidge M, Radomski MW, Gilmer JF. Nitric oxide-matrix metaloproteinase-9 interactions: biological and pharmacological significance: NO and MMP-9 interactions. Biochim Biophys Acta. 2014;1843(3):603–617.
   Web of Science ®Google Scholar
• Peppin GJ, Weiss SJ. Activation of the endogenous metalloproteinase, gelatinase, by triggered human neutrophils. Proc Natl Acad Sci U S A. 1986;83(12):4322–4326. doi:10.1073/pnas.83.12.4322
   PubMed Web of Science ®Google Scholar
• Bannikov GA, Karelina TV, Collier IE, Marmer BL, Goldberg GI. Substrate Binding of Gelatinase B Induces Its Enzymatic Activity in the Presence of Intact Propeptide. J Biol Chem. 2002;277(18):16022–16027. doi:10.1074/jbc.M110931200
   PubMed Web of Science ®Google Scholar
• Paquette B, Bisson M, Therriault H, et al. Activation of matrix metalloproteinase-2 and −9 by 2- and 4-hydroxyestradiol. J Steroid Biochem Mol Biol. 2003;87(1):65–73. doi:10.1016/S0960-0760(03)00386-8
   Web of Science ®Google Scholar
• Bonnefont-Rousselot D. Glucose and reactive oxygen species. Curr Opin Clin Nutr Metab Care. 2002;5(5):561–568. doi:10.1097/00075197-200209000-00016
   PubMed Web of Science ®Google Scholar
• Elburki MS, Moore DD, Terezakis NG, et al. A novel chemically modified curcumin reduces inflammation-mediated connective tissue breakdown in a rat model of diabetes: periodontal and systemic effects. J Periodontal Res. 2017;52(2):186–200. doi:10.1111/jre.12381
   PubMed Web of Science ®Google Scholar
• Genco RJ, Grossi SG, Ho A, Nishimura F, Murayama Y, Proposed Model A. Linking inflammation to obesity, diabetes, and periodontal infections. J Periodontol. 2005;76(11S):2075–2084. doi:10.1902/jop.2005.76.11-S.2075
   Google Scholar
• Moutsopoulos NM, Madianos PN. Low-grade inflammation in chronic infectious diseases: paradigm of periodontal infections. Ann N Y Acad Sci. 2006;1088:251–264. doi:10.1196/annals.1366.032
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327–334. doi:10.1001/jama.286.3.327
   PubMed Web of Science ®Google Scholar
• Löe H. Periodontal diseases: a brief historical perspective. Periodontology. 1993;2:7–12. doi:10.1111/j.1600-0757.1993.tb00215.x
   Google Scholar
• Löe H. Periodontal disease. The sixth complication of diabetes mellitus. Diabetes Care. 1993;16(1):329–334.
   PubMed Web of Science ®Google Scholar
• Frankwich K, Tibble C, Torres-Gonzalez M, et al. Proof of Concept: matrix metalloproteinase inhibitor decreases inflammation and improves muscle insulin sensitivity in people with type 2 diabetes. J Inflamm. 2012;9(1):35. doi:10.1186/1476-9255-9-35
   Google Scholar
• Deng J, Golub LM, Lee H-M, et al. A novel chemically-modified curcumin 2.24: short-term systemic therapy for natural periodontitis in dogs. Front Dent Med. 2021;2(5). doi:10.3389/fdmed.2021.609795
   Google Scholar
• Deng J, Golub LM, Lee HM, et al. Chemically-modified curcumin 2.24: a novel systemic therapy for natural periodontitis in dogs. J Exp Pharmacol. 2020;12:47–60. doi:10.2147/JEP.S236792
   PubMedGoogle Scholar
• Deng J, Golub LM, Lee HM, et al. A novel modified-curcumin promotes resolvin-like activity and reduces bone loss in diabetes-induced experimental periodontitis. J Inflamm Res. 2021;14:5337–5347. doi:10.2147/JIR.S330157
   PubMed Web of Science ®Google Scholar
• Elburki MS, Rossa C, Guimaraes MR, et al. A novel chemically modified curcumin reduces severity of experimental periodontal disease in rats: initial observations. Mediators Inflamm. 2014;2014:959471. doi:10.1155/2014/959471
   PubMed Web of Science ®Google Scholar
• Elburki MS, Rossa C, Guimarães-Stabili MR, et al. A chemically modified curcumin (CMC 2.24) inhibits nuclear factor κB activation and inflammatory bone loss in murine models of LPS-induced experimental periodontitis and diabetes-associated natural periodontitis. Inflammation. 2017;40(4):1436–1449. doi:10.1007/s10753-017-0587-4
   PubMed Web of Science ®Google Scholar
• Bhatt HD, McClain, SA, Lee HM et al. The maximum-tolerated-dose and pharmacokinetics of a novel chemically-modified-curcumin in rats. J Exp Pharmacol. 2022;14:73–85. doi:10.2147/JEP.S341927
   PubMedGoogle Scholar
• Golub LM, Lee HM. Periodontal therapeutics: current host-modulation agents and future directions. Periodontology. 2020;82(1):186–204. doi:10.1111/prd.12315
   Google Scholar
• Gu Y, Deng J, Lee H, et al. Chemically-modified-curcumin: resolvin activity in experimental diabetes. J Dent Res. 2017;96(Special issue A):1173.
   Google Scholar
• Gu Y, Lee HM, Napolitano N, et al. 4-methoxycarbonyl curcumin: a unique inhibitor of both inflammatory mediators and periodontal inflammation. Mediators Inflamm. 2013;2013:329740. doi:10.1155/2013/329740
   PubMed Web of Science ®Google Scholar
• Kim J, Lee HM, Golub LM, Gu Y. Antioxidant activity of a novel chemically-modified-curcumin compound (CMC 2.24). J Dent Res. 2019;11(Spec Iss 98):0912.
   Google Scholar
• Elburki MS. A Novel Chemically Modified Curcumin as A Pleiotropic MMP-Inhibitor: Therapeutic Potential in Locally- And Systemically-Induced Periodontal (And Other) Connective Tissue Breakdown [Doctoral]. Stony Brook: Stony Brook University; 2015.
   Google Scholar
• Deng J. A Novel Chemically-Modified Curcumin: Pleiotropic Resolvin-Like Activity Reduces Inflammation/Collagenolysis During Periodontitis and Diabetes [Doctoral Thesis Dissertation]. Stony Brook: Stony Brook University; 2019.
   Google Scholar
• Deng J, Gu Y, Lee H, et al. Novel chemically-modified-curcumin: resolution of cytokines and MMPs in cell culture. J Dent Res. 2018;97(Special Issue A):0129.
   Google Scholar
• Zhang Y, McClain SA, Lee HM, et al. A novel chemically modified curcumin “Normalizes” wound-healing in rats with experimentally induced type I diabetes: initial studies. J Diabetes Res. 2016;2016:5782904. doi:10.1155/2016/5782904
   PubMed Web of Science ®Google Scholar
• Cengiz IF, Oliveira JM, Reis RL. Micro-CT - A digital 3D microstructural voyage into scaffolds: a systematic review of the reported methods and results. Biomater Res. 2018;22:26. doi:10.1186/s40824-018-0136-8
   PubMedGoogle Scholar
• Ramamurthy NS, Golub LM. Diabetes increases collagenase activity in extracts of rat gingiva and skin. J Periodontal Res. 1983;18(1):23–30. doi:10.1111/j.1600-0765.1983.tb00331.x
   Web of Science ®Google Scholar
• Golub LM, Evans RT, McNamara TF, Lee HM, Ramamurthy NS. A non-antimicrobial tetracycline inhibits gingival matrix metalloproteinases and bone loss in Porphyromonas gingivalis-induced periodontitis in rats. Ann N Y Acad Sci. 1994;732:96–111. doi:10.1111/j.1749-6632.1994.tb24728.x
   PubMed Web of Science ®Google Scholar
• Golub LM, Ramamurthy NS, Llavaneras A, et al. A chemically modified nonantimicrobial tetracycline (CMT-8) inhibits gingival matrix metalloproteinases, periodontal breakdown, and extra-oral bone loss in ovariectomized rats. Ann N Y Acad Sci. 1999;878(1):290–310. doi:10.1111/j.1749-6632.1999.tb07691.x
   Google Scholar
• Lee HM, Golub LM, Cao J, et al. CMT-3, a non-antimicrobial tetracycline (TC), inhibits MT1-MMP activity: relevance to cancer. Curr Med Chem. 2001;8(3):257–260. doi:10.2174/0929867013373660
   PubMed Web of Science ®Google Scholar
• Park CH, Abramson ZR, Taba M, et al. Three-dimensional micro-computed tomographic imaging of alveolar bone in experimental bone loss or repair. J Periodontol. 2007;78(2):273–281. doi:10.1902/jop.2007.060252
   PubMed Web of Science ®Google Scholar
• Serhan CN, Levy BD. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. J Clin Invest. 2018;128(7):2657–2669. doi:10.1172/JCI97943
   PubMed Web of Science ®Google Scholar
• Serhan CN, Chiang N. Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br J Pharmacol. 2008;153(S1):S200–S315. doi:10.1038/sj.bjp.0707489
   Google Scholar
• Van Dyke TE. Pro-resolving mediators in the regulation of periodontal disease. Mol Aspects Med. 2017;58:21–36. doi:10.1016/j.mam.2017.04.006
   PubMed Web of Science ®Google Scholar
• Serhan CN. Controlling the resolution of acute inflammation: a new genus of dual anti‐inflammatory and proresolving mediators. J Periodontol. 2008;79:1520–1526. doi:10.1902/jop.2008.080231
   PubMed Web of Science ®Google Scholar
• Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol. 2008;8(5):349–361. doi:10.1038/nri2294
   PubMed Web of Science ®Google Scholar
• Roberts WE, Simmons KE, Garetto LP, DeCastro RA. Bone physiology and metabolism in dental implantology: risk factors for osteoporosis and other metabolic bone diseases. Implant Dent. 1992;1(1):11–21. doi:10.1097/00008505-199200110-00002
   Google Scholar
• Melescanu-Imre M, Preoteasa E. Mandibular panoramic indexes predictors of skeletal osteoporosis for implant therapy. Curr Health Sci J. 2009;35:220–225.
   Google Scholar
• Ryan M, Ramamurthy N, Sorsa T, Golub L. MMP-mediated events in diabetes. Ann N Y Acad Sci. 1999;878:311–334. doi:10.1111/j.1749-6632.1999.tb07692.x
   PubMed Web of Science ®Google Scholar
• Rai B, Kharb S, Jain R, Anand SC. Biomarkers of periodontitis in oral fluids. J Oral Sci. 2008;50(1):53–56. doi:10.2334/josnusd.50.53
   PubMedGoogle Scholar
• Gruber BL, Sorbi D, French DL, et al. Markedly elevated serum MMP-9 (Gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. Clin Immunol Immunopathol. 1996;78(2):161–171. doi:10.1006/clin.1996.0025
   Google Scholar
• Mondal S, Adhikari N, Banerjee S, Amin SA, Jha T. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: a minireview. Eur J Med Chem. 2020;194:112260. doi:10.1016/j.ejmech.2020.112260
   PubMed Web of Science ®Google Scholar
• Domenyuk D, Samedov F, Dmitrienko S, et al. Matrix metalloproteinases and their tissue inhibitors in the pathogenesis of periodontal diseases in type 1 diabetes mellitus. Archiv Euro Medica. 2019;9(3):81. doi:10.35630/2199-885X/2019/9/3.25
   Google Scholar
• Sorsa T, Alassiri S, Grigoriadis A, et al. Active MMP-8 (aMMP-8) as a grading and staging biomarker in the periodontitis classification. Diagnostics. 2020;10(2):61. doi:10.3390/diagnostics10020061
   Web of Science ®Google Scholar
• Sorsa T, Gursoy UK, Nwhator S, et al. Analysis of matrix metalloproteinases, especially MMP-8, in gingival crevicular fluid, mouthrinse and saliva for monitoring periodontal diseases. Periodontology. 2016;70(1):142–163. doi:10.1111/prd.12101
   Google Scholar
• Sorsa T, Hernández M, Leppilahti J, et al. Detection of gingival crevicular fluid MMP-8 levels with different laboratory and chair-side methods. Oral Dis. 2010;16(1):39–45. doi:10.1111/j.1601-0825.2009.01603.x
   PubMed Web of Science ®Google Scholar
• Sorsa T, Mäntylä P, Tervahartiala T, et al. MMP activation in diagnostics of periodontitis and systemic inflammation. J Clin Periodontol. 2011;38(9):817–819. doi:10.1111/j.1600-051X.2011.01753.x
   PubMed Web of Science ®Google Scholar
• Sorsa T, Sahni V, Buduneli N, et al. Active matrix metalloproteinase-8 (aMMP-8) point-of-care test (POCT) in the COVID-19 pandemic. Expert Rev Proteomics. 2021;18(8):707–717. doi:10.1080/14789450.2021.1976151
   PubMed Web of Science ®Google Scholar
• Sorsa T, Tervahartiala T, Leppilahti J, et al. Collagenase-2 (MMP-8) as a point-of-care biomarker in periodontitis and cardiovascular diseases. Therapeutic response to non-antimicrobial properties of tetracyclines. Pharmacol Res. 2011;63(2):108–113.
   PubMed Web of Science ®Google Scholar
• Kang Q, Yang C. Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol. 2020;37(101799):2213–2317.
   Google Scholar
• Uemura S, Matsushita H, Li W, et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity. Circ Res. 2001;88(12):1291–1298. doi:10.1161/hh1201.092042
   PubMed Web of Science ®Google Scholar
• Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem. 1999;274(31):21491–21494. doi:10.1074/jbc.274.31.21491
   PubMed Web of Science ®Google Scholar